

DAFTAR PUSTAKA

1. Dougherty SD, Carapetis J, Zühlke L, Wilson N. Acute rheumatic fever and rheumatic heart disease. Elsevier; 2021. p. 69–75.
2. Marijon E, Mocumbi A, Narayanan K, Jouven X, Celermajer DS. Persisting burden and challenges of rheumatic heart disease. *Eur Heart J*. 2021;42(34):3338–48.
3. Liang Y, Yu D, Lu Q, Zheng Y, Yang Y. The rise and fall of acute rheumatic fever and rheumatic heart disease: a mini review. *Front Cardiovasc Med*. 2023;10.
4. Restuningtyas A, Maulidya A, Saroh SA. Penyakit jantung reumatik, manifestasi klinis dan penanganannya. 2021.
5. Ou Z, Yu D, Liang Y, Wu J, He H. Global burden of rheumatic heart disease: trends from 1990 to 2019. *Arthritis Res Ther*. 2022;24(1):138.
6. World Health Organization. Rheumatic heart disease [Internet]. 2020 [cited 2025 Jan 8]. Available from: <https://www.who.int/newsroom/factsheets/detail/rheumatic-heart-disease>
7. Pusparani C, Rahayuningsih E, Gurnida D. Korelasi antara nilai red cell distribution width dengan fungsi ventrikel kiri pada anak dengan gagal jantung akibat penyakit jantung rematik. 2021;23.
8. Christia S. Skrining penyakit jantung rematik pada anak: evaluasi berdasarkan pemeriksaan ekokardiografi: review sistematis. *NN-Journal of Advance Research in Medical & Health Science*. 2022;8(9):1–6.
9. Rose A. A school-based study of the prevalence of rheumatic heart disease in Bali, Indonesia. *Yale Medicine Thesis Digital Library*; 2024.
10. Ardini TW, Ilyas KK, Nasution AN, Ketaren AP, Napitupulu BG. Early detection of subclinical rheumatic heart disease through echocardiographic screening: a study in North Sumatra, Indonesia. *Heart Sci J*. 2024;5(3):55–9.
11. Salsabila GD. Profil klinis pasien penyakit jantung rematik di poliklinik RSUP Dr. M. Djamil Padang tahun 2015–2017. Padang: Universitas Andalas; 2018.
12. Machuca JN. From strep infection to a streptococcal heart pattern in rheumatic fever: a case report. *Cureus*. 2024.
13. Mengie A, Admassu E, Habtamu D, Berhie AY, Mulatu K, Lidetu T, et al. Prevalence and associated factors of atrial fibrillation among patients with rheumatic heart disease attending public referral hospitals in Bahir Dar city, Northwest Ethiopia, 2023. *BMC Cardiovasc Disord*. 2024;24(1):434.

14. Cunha C, Amboss ND, de Amorim GDT, Weksler C, dos Santos MC. Ischemic stroke in a young patient with rheumatic mitral stenosis. *JACC Case Rep.* 2024;29(20):102674.
15. Chen Y, Wang L, Ma D, Cui Z, Liu Y, Pang Q, et al. Research on rheumatic heart disease from 2013 to early 2024: a bibliometric analysis. *J Cardiothorac Surg.* 2024;19(1):659.
16. Noubiap JJ, Nyaga UF, Ndoadoumgue AL, Nkeck JR, Ngouo A, Bigna JJ. Meta-analysis of the incidence, prevalence, and correlates of atrial fibrillation in rheumatic heart disease. *Glob Heart.* 2020;15(1).
17. Shenthur J. Management of atrial fibrillation in rheumatic heart disease. *Heart Rhythm O2.* 2022;3(6):752–9.
18. Karthikeyan G, Ntsekhe M, Islam S, Rangarajan S, Avezum A, Benz A, et al. Mortality and morbidity in adults with rheumatic heart disease. *JAMA.* 2024;332(2):133–40.
19. Yuniadi Y, Hanafy DA, Raharjo SB, Tondas AE, Maharani E, Hermanto DY, et al. 2014 Indonesian Heart Association guidelines of management of atrial fibrillation. *J Kardiologi Indones.* 2014;35(2):102–35.
20. Husniyah B, Herwanto B, Handayani N. Profile of atrial fibrillation of outpatients in functional medical staff of cardiology in RSUD Dr. Soetomo during February 2018. Surabaya; 2018.
21. Soesanto AM, Almazini P, Ariani R, Rudiktyo E, Ardini TW, Mumpuni H, et al. Characteristics and problems of rheumatic heart disease in Indonesia. *JACC Asia.* 2025;5(9):1171–83.
22. Faisal I. Karakteristik pasien penderita atrial fibrilasi di RSUP Dr. Wahidin Sudirohusodo, Makassar. Makassar: Universitas Hasanuddin; 2020.
23. Azmi AB. Profil klinis pasien fibrilasi atrium di RSUP Dr. M. Djamil Padang periode 1 Januari–31 Desember 2017. Padang: Universitas Andalas; 2017.
24. World Heart Federation. Rheumatic heart disease [Internet]. cited 2025 Jan 8. Available from: <https://world-heart-federation.org/what-we-do/rheumatic-heart-disease/>
25. Pangestu NLDW, Wita IW, Antara IMPS, Yasmin ADA. Hubungan antara tingkat kepatuhan prevensi sekunder dengan perburukan penyakit pada pasien jantung rematik di RSUP Sanglah Denpasar. *E-Jurnal Medika Udayana.* 2024;13(9):106.
26. Yousif I, Fadlelmoula S, Ali EM, Alhindi S, Mohammadat D, Elkhidir IH, et al. Risk factors of rheumatic heart disease in a children's hospital in Khartoum: a case-control study. *Cureus.* 2024.

27. Riaz BK, Selim S, Karim MN, Chowdhury KN, Chowdhury SH, Rahman MR. Risk factors of rheumatic heart disease in Bangladesh: a case-control study. *J Health Popul Nutr.* 2023;31(1).
28. Hempenstall A, Howell E, Kang K, Chau KWT, Browne A, Kris E, et al. Echocardiographic screening detects a significant burden of rheumatic heart disease in Australian Torres Strait Islander children and missed opportunities for its prevention. *Am J Trop Med Hyg.* 2021;104(4):1211–4.
29. Sharma N, Toor D. Impact of socio-economic factors on increased risk and progression of rheumatic heart disease in developing nations. *Curr Infect Dis Rep.* 2019;21(6):21.
30. Abdelsayed K, Ali HT, Helal MB, Assar A, Madany M, Gabra MD, et al. Assessing the knowledge, attitude, and practice of frontline physicians in Egyptian university hospitals regarding pharyngitis and acute rheumatic fever: a cross-sectional study that calls for action. *BMC Public Health.* 2024;24(1):2235.
31. Kazahura PT, Mushi TL, Pallangyo P, Janabi M, Kisenge R, Albaghdadi M, et al. Prevalence and risk factors for subclinical rheumatic heart disease among primary school children in Dar es Salaam, Tanzania: a community based cross-sectional study. *BMC Cardiovasc Disord.* 2021;21(1):610.
32. Riaz S, Kumari V, Shahnawaz K, Zahoor F, Khan MA, Liaqat S, et al. Clinical profile of acute rheumatic fever in children in Pakistan: a study at a tertiary care hospital. *Prof Med J.* 2023;30(08):1063–7.
33. Trisna Ardani NI, Gede Aditya. Rheumatic heart disease in east of Bali Indonesia. *Bioscientia Medicina.* 2024;8(8):4705–11.
34. Thiongane A, Ba A, Ly F, Ndongo AA, Boiro D, Kéita Y, et al. Epidemiological investigation of rheumatic heart disease in the emergency department in dakar: a descriptive analysis. *Asian Journal of Pediatric Research.* 2023 Dec 1;13(4):133–9.
35. Hibino M, Shimamura J, Verma R, Dhingra N, Yanagawa B, Bhatt D, et al. Sex differences in mortality trends of rheumatic heart disease in high-income countries. *Circulation.* 2023;148.
36. Auala T, Zavale BG, Mbakwem AÇ, Mocumbi AO. Acute rheumatic fever and rheumatic heart disease: highlighting the role of group A Streptococcus in the global burden of cardiovascular disease. *Pathogens.* 2022;11(5):496.
37. Gaya ML, Hariyanto D. Demam rematik akut pada anak. *Human Care J.* 2021;6(2):328.
38. Cannon J, Bessarab DC, Wyber R, Katzenellenbogen JM. Public health and economic perspectives on acute rheumatic fever and rheumatic heart disease. *Med J Aust.* 2019;211(6):250.

39. Düzgün N, Duman T, Haydardedeoğlu FE, Tutkak H. Cytotoxic T lymphocyte-associated antigen-4 polymorphism in patients with rheumatic heart disease. *Tissue Antigens*. 2009;74(6):539–42.
40. Sikder S. Determination of the role of group A Streptococcus in the pathogenesis of rheumatic heart disease using a rat model. 2018.
41. Martins CO, Demarchi L, Ferreira FM, Pomerantzeff PMA, Brandao C, Sampaio RO, et al. Rheumatic heart disease and myxomatous degeneration: differences and similarities of valve damage resulting from autoimmune reactions and matrix disorganization. *PLoS One*. 2017;12(1).
42. Burova LA, Suvorov AN, Totolian AA. Streptococcus pyogenes: phenomenon of nonimmune binding of human immunoglobulins and its role in pathology. *Med Immunol*. 2022;24(2):217–34.
43. McEwan TBD, Sanderson-Smith ML, Sluyter R. Purinergic signalling in group A Streptococcus pathogenesis. *Front Immunol*. 2022;13.
44. Sharma S, Chakraborti A. Unfurling the role of genetic polymorphism in rheumatic heart disease pathogenesis. *Cardiol Cardiovasc Med*. 2021;5(4).
45. Lumngwena E, Parker I, Mokaila D, Skatulla S, Blackburn J. The pathophysiology of RHD and outstanding gaps. *SA Heart*. 2022;19(1).
46. Zhang Q-chun, Yin H-hui, Yin B-liang. Concentration and significance of s-ICAM-1, s-VCAM-1, and vWF in the plasma of patients with rheumatic heart disease. *Zhong Nan Da Xue Xue Bao Yi Xue Ban*. 2005;30(4):407–9.
47. Xian S, Li Y, Bai L, Tang S, Meng Z, Wen H, et al. Potential involvement of M1 macrophage and VLA4/VCAM-1 pathway in the valvular damage due to rheumatic heart disease. *Front Biosci (Landmark Ed)*. 2024;29(6).
48. Conrado Dos Santos WL, Verney RN, de Montclos H, Veyseyre C, Carraz M, Grimaud JA. Connective tissue changes in rheumatic heart disease. *J Submicrosc Cytol Pathol*. 1991;23(2):213–20.
49. Ahmad F, Arshed AR, Mumtaz MH, Amjad F, Tariq M, Fatima A, et al. Analysis of the correlation between the expression of T-helper type 17 cell-related cytokines and valve damage in rheumatic heart disease. *Cureus*. 2024.
50. Tito DJ, Yanni M. Perubahan morfologi katup mitral pada demam rematik akut dan penyakit jantung rematik. *Human Care J*. 2020;5(2):455.
51. Otto C, Bonow R. Valvular heart disease: a companion to Braunwald's heart disease. 5th ed. Elsevier; 2020. p. 14–17.
52. Lilly LS. Pathophysiology of heart disease. 6th ed. 2016. p. 192–220.

53. Suwari CIP, Gede WD. Mitral stenosis berat pada penyakit jantung rematik. *J Kesehatan Andalas*. 2023;12(2):93.
54. Dall AQK, Shaikh MK, Shah SZA, Devrajani T, Memon AS, Karim I, et al. Clinical and echocardiographic profile of rheumatic heart disease: a cross-sectional study. *J Pharm Res Int*. 2021;:1–7.
55. Rwebembera J, Marangou J, Mwitwa JC, Mocumbi AO, Mota C, Okello E, et al. 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease. *Nat Rev Cardiol*. 2024;21(4):250–63.
56. PERKI. Panduan praktik klinis (PPK) dan clinical pathway (CP) penyakit jantung dan pembuluh darah. 2016.
57. Ralph AP, Currie BJ. Therapeutics for rheumatic fever and rheumatic heart disease. *Aust Prescr*. 2022;45(4):104–12.
58. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, et al. Contemporary diagnosis and management of rheumatic heart disease: implications for closing the gap: a scientific statement from the American Heart Association. *Circulation*. 2020;142(20).
59. Dougherty S, Essop MR, Webb R, Price S, Wilson N. Complications of rheumatic heart disease and acute emergencies. In: *Acute rheumatic fever and rheumatic heart disease*. Elsevier; 2021. p. 301–36.
60. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2024;149:E1–156.
61. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2024;45(36):3314–414.
62. PERKI. Pedoman tatalaksana fibrilasi atrium [Internet]. 2019 [cited 2025 Mar 26]. Available from: www.transmedicalinstitute.com
63. Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. *BMJ*. 2018;k1453.
64. Cunha PS, Laranjo S, Heijman J, Oliveira MM. The atrium in atrial fibrillation: a clinical review on how to manage atrial fibrotic substrates. *Front Cardiovasc Med*. 2022;9.

65. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(1):1–39.e14.
66. Cho IJ, Jeong H, Choi JY, Lee SE, Chang HJ. Prognostic implications of the left atrial volume index in patients with progressive mitral stenosis. *J Cardiovasc Imaging*. 2019;27(2):122.
67. Maeder MT, Weber L, Buser M, Gerhard M, Haager PK, Maisano F, et al. Pulmonary hypertension in aortic and mitral valve disease. *Front Cardiovasc Med*. 2018;5.
68. Dreyfus GD, Martin RP, Chan KMJ, Dulguerov F, Alexandrescu C. Functional tricuspid regurgitation. *J Am Coll Cardiol*. 2015;65(21):2331–6.
69. Gaasch WH, Meyer TE. Left ventricular response to mitral regurgitation. *Circulation*. 2008;118(22):2298–303.
70. Beppu S, Nimura Y, Sakakibara H, Nagata S, Park YD, Izumi S. Smoke-like echo in the left atrial cavity in mitral valve disease: its features and significance. *J Am Coll Cardiol*. 1985;6(4):744–9.
71. Fatkin D, Herbert E, Feneley MP. Hematologic correlates of spontaneous echo contrast in patients with atrial fibrillation and implications for thromboembolic risk. *Am J Cardiol*. 1994;73(9):672–6.
72. Brandes A. Rheumatic mitral valve stenosis and atrial fibrillation: vicious twins. *Int J Cardiol*. 2024;395:131566.
73. Masturoh I, Anggita N. Metodologi penelitian kesehatan Kemenkes. 2018.
74. KBBI. Definisi operasional usia [Internet]. [cited 2025 Mar 26]. Available from: <https://kbbi.web.id/usia>
75. Shastri MH, Mistry HP, Vinod V, Rathod VM, Sirajwala AA, Patel NS, et al. Clinical evaluation and investigations of atrial fibrillation in rheumatic mitral valve disease: an observational study in a tertiary care hospital in western India. *Apollo Med*. 2024;21(2):101–6.
76. Badan Pusat Statistik. Detail metadata variabel statistik jenis kelamin [Internet]. [cited 2025 Mar 26]. Available from: <https://sirusa.web.bps.go.id/metadata/variabel/179531>
77. Badan Pusat Statistik. Peraturan Kepala BPS Nomor 120 Tahun 2020 tentang Klasifikasi Desa Perkotaan dan Perdesaan di Indonesia [Internet]. 2020.
78. KBBI. Definisi operasional pendidikan [Internet]. [cited 2025 Mar 26]. Available from: <https://kbbi.web.id/pendidikan>

79. Du Bois D, Du Bois EF. Simplified calculation of body-surface area. *N Engl J Med*. 1987;317(17):1098.
80. Negi P, Kumar S. Heart failure in rheumatic fever and rheumatic heart disease. *Heart Fail J India*. 2023;1(1):48.
81. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(1):1–39.e14.
82. Negi PC, Sondhi S, Rana V, Rathoure S, Kumar R, Kolte N, et al. Prevalence, risk determinants and consequences of atrial fibrillation in rheumatic heart disease: 6 years hospital-based Himachal Pradesh RF/RHD registry. *Indian Heart J*. 2018;70:S68–73.
83. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. *Front Neuroendocrinol*. 2014;35(3):347–69.
84. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(1):1–39.e14.
85. Westerman S, Wenger N. Gender differences in atrial fibrillation: a review of epidemiology, management, and outcomes. *Curr Cardiol Rev*. 2019;15(2):136–44.
86. Bregani ER, Valcarengi C, Conti M. A survey on a rural in-hospital population diagnosed with atrial fibrillation in West Shewa region, Ethiopia. *J Public Health (Bangkok)*. 2021;43(2):325–32.
87. Dhungana SP, Nepal R, Ghimire R. Prevalence and factors associated with atrial fibrillation among patients with rheumatic heart disease. *J Atr Fibrillation*. 2019;12(4).
88. Zühlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). *Eur Heart J*. 2015;36(18):1115–22.
89. Remenyi B, Carapetis J, Wyber R, Taubert K, Mayosi BM. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. *Nat Rev Cardiol*. 2013;10(5):284–92.
90. Joglar J, et al. Clinical update adapted from: 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. 2023.

91. Ribeiro ASF, Zero BE, Lopez-Espuela F, Sanchez R, Fernandes VS. Cardiac system during the aging process. *Aging Dis.* 2023;0.
92. Saggu DK, Rangaswamy VV, Yalagudri S, Sundar G, Reddy NK, Shah V, et al. Prevalence, clinical profile, and stroke risk of atrial fibrillation in rural Andhra Pradesh, India (the AP-AF study). *Indian Heart J.* 2022;74(2):86–90.
93. Corica B, Romiti GF, Basili S, Proietti M. Prevalence of new-onset atrial fibrillation and associated outcomes in patients with sepsis: a systematic review and meta-analysis. *J Pers Med.* 2022;12(4):547.
94. Long B, Brady WJ, Gottlieb M. Emergency medicine updates: atrial fibrillation with rapid ventricular response. *Am J Emerg Med.* 2023;74:57–64.
95. Rienstra M, Tzeis S, Bunting KV, Caso V, Crijns HJGM, De Potter TJR, et al. Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects. *Europace.* 2024;26(12).
96. Gomes NFA, Silva VR, Levine RA, Esteves WAM, de Castro ML, Passos LSA, et al. Progression of mitral regurgitation in rheumatic valve disease: role of left atrial remodeling. *Front Cardiovasc Med.* 2022;9.
97. Opara CC, Lan RH, Rwebembera J, Okello E, Watkins DA, Chang AY, et al. Outcomes and care quality metrics for people living with rheumatic heart disease and atrial fibrillation in Uganda. *Heart Rhythm O2.* 2024;5(4):201–8.
98. Stojadinović P, Deshraj A, Wichterle D, Fukunaga M, Peichl P, Kautzner J, et al. The hemodynamic effect of simulated atrial fibrillation on left ventricular function. *J Cardiovasc Electrophysiol.* 2022;33(12):2569–77.
99. Rienstra M, Tzeis S, Bunting KV, Caso V, Crijns HJGM, De Potter TJR, et al. Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects. *Europace.* 2024;26(12).
100. Chamberlain-Salaun J, Mills J, Kevat PM, Rémond MGW, Maguire GP. Sharing success: understanding barriers and enablers to secondary prophylaxis delivery for rheumatic fever and rheumatic heart disease. *BMC Cardiovasc Disord.* 2016;16(1):166.
101. Liuzzo G, Patrono C. Vitamin K antagonists remain the INVICTUS standard of care for patients with rheumatic heart disease and atrial fibrillation. *Eur Heart J.* 2023;44(6):443–4.
102. Napoli F, Vella C, Ferri L, Ancona M, Bellini B, Russo F, et al. Rheumatic and degenerative mitral stenosis: from an iconic clinical case to the literature review. *J Cardiovasc Dev Dis.* 2024;11(5):153.

103. Passos LSA, Nunes MCP, Aikawa E. Rheumatic heart valve disease pathophysiology and underlying mechanisms. *Front Cardiovasc Med.* 2021;7.
104. Brandes A. Rheumatic mitral valve stenosis and atrial fibrillation: vicious twins. *Int J Cardiol.* 2024;395:131566.
105. Figueiredo FA, Esteves WAM, Hung J, Gomes NFA, Taconeli CA, Pantaleão AN, et al. Left atrial function in patients with rheumatic mitral stenosis: addressing prognostic insights beyond atrial fibrillation prediction. *Eur Heart J Imaging Methods Pract.* 2024;2(2).
106. Kim HJ, Cho GY, Kim YJ, Kim HK, Lee SP, Kim HL, et al. Development of atrial fibrillation in patients with rheumatic mitral valve disease in sinus rhythm. *Int J Cardiovasc Imaging.* 2015;31(4):735–42.
107. John B, Lau CP. Atrial fibrillation in valvular heart disease. *Card Electrophysiol Clin.* 2021;13(1):113–22.
108. Richter MJ, Zedler D, Berliner D, Douschan P, Gall H, Ghofrani HA, et al. Clinical relevance of right atrial functional response to treatment in pulmonary arterial hypertension. *Front Cardiovasc Med.* 2021;8.
109. Neema PK, Panidapu N. The mechanisms and pathophysiology of mitral regurgitation: a narrative review. *Ann Card Anaesth.* 2025;28(2):109–18.
110. Magne J, Pibarot P, Sengupta PP, Donal E, Rosenhek R, Lancellotti P. Pulmonary hypertension in valvular disease. *JACC Cardiovasc Imaging.* 2015;8(1):83–99.
111. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *Lancet.* 2009;373(9658):155–66.
112. Rudiktyo E, Soesanto AM, Cramer MJ, Yonas E, Teske AJ, Siswanto BB, et al. Global left ventricular myocardial work efficiency in patients with severe rheumatic mitral stenosis and preserved left ventricular ejection fraction. *J Cardiovasc Imaging.* 2023;31(4):191.
113. Lai WT, Chen IC, Hsiung MC, Lin TC, Huang KC, Chang CY, et al. Recovery of left ventricular function after surgery for aortic and mitral regurgitation with heart failure. *Int J Cardiol Cardiovasc Risk Prev.* 2024;23:200329.
114. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography. *J Am Soc Echocardiogr.* 2010;23(7):685–713.

115. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, et al. Right heart adaptation to pulmonary arterial hypertension. *J Am Coll Cardiol*. 2013;62(25):D22–33.
116. Patlolla SH, Schaff HV, Nishimura RA, Stulak JM, Chamberlain AM, Pislaru SV, et al. Incidence and burden of tricuspid regurgitation in patients with atrial fibrillation. *J Am Coll Cardiol*. 2022;80(24):2289–98.
117. Bombace S, Fortuni F, Viggiani G, Meucci MC, Condorelli G, Carluccio E, et al. Right heart remodeling and outcomes in patients with tricuspid regurgitation. *JACC Cardiovasc Imaging*. 2024;17(6):595–606.

